Chen Hongming 4
4 · Kala Pharmaceuticals, Inc. · Filed Apr 1, 2020
Insider Transaction Report
Form 4
Chen Hongming
Chief Scientific Officer10% Owner
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2020-03-30−31,000→ 75,236 totalExercise: $2.30Exp: 2024-10-01→ Common Stock (31,000 underlying) - Exercise/Conversion
Common Stock
2020-03-30$2.30/sh+31,000$71,300→ 86,849 total
Footnotes (1)
- [F1]The option became fully vested on July 21, 2018.